Notice

J INTS BIO, M.D Anderson Cancer Center joint development - oral HSP90 inhibitor 'JIN-001', presentation of preclinical assessment at 2022 SNO Annual Meeting

SEOUL, South Korea, Nov. 23, 2022 /PRNewswire/ -- J INTS BIO announced that the preclinical assessment of JIN-001 or MPT0B640, a novel, orally adminis 2022.11.23

Notice

J INTS BIO, Novel Oral 4th Generation EGFR TKI 'JIN-A02' - Phase 1/2 IND approved by US FDA

- First patient expected in December 2022SEOUL, South Korea, Nov. 10, 2022 /PRNewswire/ -- J INTS BIO announced on November 9th that it had received a 2022.11.10

Notice

J INTS BIO’s Novel Oral 4th Generation EGFR-TKI ‘JIN-A02’ effective against both cis and trans isomers of C797S mutations - ESMO 2022

SEOUL, South Korea, Sept. 15, 2022 /PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered 4th generation EGFR- 2022.09.16

Notice

J INTS BIO successfully held its 1st International Advisory Board Meeting for its Novel Oral 4th Generation EGFR TKI (JIN-A02) in Vienna, Austria during WCLC

SEOUL, South Korea, Aug. 19, 2022 /PRNewswire/ -- J INTS BIO announced that it held its 1st International Advisory Board Meeting for its Novel Oral 4t 2022.08.19

Notice

J INTS BIO, Oral presentation of Preclinical results of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' at the 2022 World Conference on Lung Cancer in Vienna, Austria (IASLC 2022 WCLC)

SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- J INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGF 2022.08.16

Notice

JIN-A02, A Novel 4th Generation EGFR TKI selected for the European Thoracic Oncology Platform - A First for Korean Pharma.

SEOUL, South Korea, Aug. 11, 2022 /PRNewswire/ -- J INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGF 2022.08.12

Notice

Prof. Cho, head of the lung cancer center at Yonsei Cancer Hospital, "J INTS BIO's new oral administration 4th generation EGFR TKI 'JIN-A02' expected to be a game changer"

SEOUL, South Korea, June 21, 2022 /PRNewswire/ -- Prof. Cho Byoung-chul at Yonsei University College of Medicine (Director, Lung Cancer Center, Yonsei 2022.06.22

Notice

J INTS BIO successfully held two Korean Advisory Board Meetings for its Novel Oral 4th Generation EGFR TKI (JIN-A02)

Members include the 10 leading NSCLC experts in Korea, discussing clinical design and R&D…SEOUL, South Korea, June 10, 2022 /PRNewswire/ -- J INTS BIO 2022.06.10

Notice

J INTS BIO 4th Generation EGFR TKI (JIN-A02) US FDA Phase 1/2 IND submission completed

SEOUL, South Korea, June 3, 2022 /PRNewswire/ -- J INTS BIO, a company specializing in the development of novel anticancer and orphan drugs, announced 2022.06.03